Xiaofang Jin

Lead the RA CMC group supporting global product development and regulatory approvals

Global RA CMC for innovative biologics/biosimilar development and marketing authorization

Work with various cross-functional teams (clinical, nonclinical, CMC, and commercial) and Contract Research Organizations (CROs)/vendors to ensure the delivery of regulatory submissions in US, EU, and Asian Pacific.

Contributed to the drug development programs across various therapeutic areas and targets (infectious disease, autoimmune disorder, cancer targeted therapy, immuno-oncology). Solid protein engineering experience, in depth knowledge of monoclonal antibodies and fragments, bispecific antibodies, antibody drug conjugate as well as emerging therapeutic modalities like bispecific T cell engagers and cell therapy.

Thesis title: Identification of novel breast cancer and melanoma avid peptides for imaging